diabetestalk.net

How Does Cycloset Work For Diabetes

Fda Approves New Diabetes Drug Cycloset

Fda Approves New Diabetes Drug Cycloset

May 7, 2009 -- The FDA has approved a new drug, called Cycloset, to improve blood sugar control in adults with type 2 diabetes , in addition to diet and exercise . Cycloset takes a new approach to treating type 2 diabetes . It boosts levels of a chemical called dopamine, which helps nerve cells communicate. Cycloset is taken orally in the morning, within two hours of waking, and with food. It's not clear how Cycloset improves glycemic control in humans. But studies in diabetic animals show that boosting dopamine activity at a particular time of day can "reset" the biological clock to improve metabolism problems related to diabetes , according to VeroScience, the company that developed Cycloset. In a yearlong trial of 3,070 adults with type 2 diabetes , Cycloset trumped a placebo at improving HbA1c levels, which gauge blood sugar control, over the previous two to three months. In that trial, 39% of patients taking Cycloset met the HbA1c goal, compared to 11% of patients taking the placebo. In addition, patients taking Cycloset were less likely to have a heart attack or stroke , or to die of heart disease . During the clinical trial , 24% of the patients in the Cycloset group dropped out of the study, compared to 15% of the patients taking placebo. Gastrointestinal side effects, particularly nausea , were the main reason patients taking Cycloset quit the study. The most commonly reported adverse events were nausea, fatigue , vomiting , headache , and dizziness . None of those cases was serious, and side effects were more likely to happen when patients first started taking Cycloset. Cycloset's active ingredient, bromocriptine mesylate, isn't a new drug. It's been used in other formulations to treat conditions including Parkinson's disease , usually at higher doses, accord Continue reading >>

Cycloset (bromocriptine Mesylate) Tablets Are A Dopamine Receptor Agonist Indicated As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus.

Cycloset (bromocriptine Mesylate) Tablets Are A Dopamine Receptor Agonist Indicated As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus.

CYCLOSET should not be used to treat type 1 diabetes or diabetic ketoacidosis. There are limited efficacy data in combination with thiazolidinediones. Efficacy has not been confirmed in combination with insulin. IMPORTANT SAFETY INFORMATION FOR CYCLOSET Do not use CYCLOSET in patients with hypersensitivity to ergot-related drugs, bromocriptine or to any of the excipients in CYCLOSET. Do not use CYCLOSET in patients with syncopal migraines. May precipitate hypotension. Do not use CYCLOSET in nursing women. May inhibit lactation. There have been postmarketing reports of stroke with bromocriptine in this patient population, although causality has not been proven. Based on CYCLOSET clinical trials, there is no evidence of increased risk for stroke when CYCLOSET is used to treat type 2 diabetes. CYCLOSET can cause orthostatic hypotension and syncope, particularly upon initiation or dose escalation. Use caution in patients taking anti-hypertensive medications. Orthostatic vital signs should be assessed prior to initiation of CYCLOSET and periodically thereafter. Advise patients during early treatment to avoid situations that could lead to injury if syncope were to occur, and to make slow postural changes. Pathological gambling and exacerbation of psychotic disorders have been reported with bromocriptine generally given in higher doses than what is approved for diabetes treatment. There have been no reported cases of psychoses or pathological gambling among CYCLOSET-treated patients in clinical trials. The use of CYCLOSET in patients with severe psychotic disorders is not recommended. CYCLOSET may cause somnolence, particularly when initiating therapy. Advise patients not to drive or operate heavy machinery if symptoms of somnolence occur. Concomitant Use of Dopamine Antagoni Continue reading >>

Cycloset

Cycloset

Cycloset is a prescription medicine approved for the treatment of diabetes. Specifically, it is used in combination with diet and exercise to help control blood sugar in people with type 2 diabetes. The medication comes in tablet form and is usually taken within two hours after waking in the morning. Some of the common side effects of this drug include dizziness, vomiting, and fatigue. Cycloset ( bromocriptine mesylate) is a prescription diabetes medication . It is approved to be used together with diet and exercise to help control blood sugar in people with type 2 diabetes . (Click Cycloset Uses for more information on what the medication is used for, including possible off-label uses.) Cycloset is made by Patheon, Inc. for VeroScience LLC. Cycloset belongs to a group of medications known as ergot alkaloids. It works as a dopamine receptor agonist, which means that it binds to and stimulates dopamine receptors. Dopamine is a neurotransmitter (a chemical that transmits signals between nerves). It is not entirely clear how Cycloset works to control blood sugar, but it is thought that stimulating dopamine receptors in the brain at certain times of the day "resets" the biological clock and improves metabolism. It is thought that seasonal changes in the metabolism of wild animals are due to similar mechanisms. For years, bromocriptine (the active ingredient in Cycloset) has been used to treat Parkinson's disease , acromegaly (a growth disorder), and hyperprolactinemia (a hormone disorder). Only recently has it been approved for treating diabetes . Continue reading >>

Fda Approves Cycloset, A Type 2 Treatment That Works On The Brain

Fda Approves Cycloset, A Type 2 Treatment That Works On The Brain

FDA Approves Cycloset, a Type 2 Treatment That Works on the Brain The U.S. Food and Drug Administration has just approved the marketing of Cycloset, a type 2 diabetes drug that works by affecting a brain chemical that helps govern metabolism. In doing so, it helps reduce the rise in blood sugar levels that typically occurs after meals. Cycloset will be offered as a monotherapy or in conjunction with sulfonylureas, metformin, or other combination type 2 drug therapies. In tests, Cycloset did two things that helped sway FDA approval. First, over a six-month trial period, 35 percent of the drugs type 2 users were able to reach target blood sugar levels, compared with 10 percent of those who were given placebos. The drug also allayed the FDAs growing concerns over an association between diabetes drugs and an increased incidence of cardiovascular disease in type 2 patients. In a 52-week study that involved 3,000 type 2 patients, those taking Cycloset experienced 42 percent fewer heart attacks than patients not taking the drug. Produced by Rhode Island-based VeroScience, Cycloset is a version of a drug called bromocriptine, which is often used at higher doses to treat Parkinsons disease. Unlike other diabetes drugs, which control insulin and glucose levels by working on the pancreas and liver, Cycloset affects dopamine levels in the brain. Dopamine is a nervous system chemical messenger that operates at low levels in people with metabolic diseases such as diabetes and metabolic syndrome. Cycloset acts as an agonist, an agent that increases dopamine activity. The increased dopamine activity helps the nervous system reset itself and establish a metabolic pattern that is less subject to glycemic highs and lows. Because some patients who take Cycloset experience dizziness and na Continue reading >>

Bromocriptine: A Dopamine Agonist For The Treatment Of Diabetes

Bromocriptine: A Dopamine Agonist For The Treatment Of Diabetes

Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h of awakening is believed to augment low hypothalamic dopamine levels and inhibit excessive sympathetic tone within the central nervous system (CNS), resulting in a reduction in postmeal plasma glucose levels due to enhanced suppression of hepatic glucose production. Bromocriptine has not been shown to augment insulin secretion or enhance insulin sensitivity in peripheral tissues (muscle). Addition of bromocriptine to poorly controlled type 2 diabetic patients treated with diet alone, metformin, sulfonylureas, or thiazolidinediones produces a 0.50.7 decrement in HbA1c. Bromocriptine also reduces fasting and postmeal plasma free fatty acid (FFA) and triglyceride levels. In a 52 double-blind, placebo-controlled study in type 2 diabetic patients, bromocriptine reduced the composite cardiovascular end point by 40%. The mechanism of the drug's beneficial effect on cardiovascular disease remains to be determined. Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance, impaired -cell function, and multiple other metabolic/endocrine abnormalities.[ 1 ] Because of its multifactorial pathogenesis, restoration of normoglycemia is difficult to achieve and requires multiple antidiabetic medications that have different mechanisms of action and can be used in combination to produce an additive effect.[ 1 , 2 ] Therefore, the development of antidiabetic agents that have novel mechanisms of action and can be used in combination with currently approved medications for the treatment of type 2 diabetes is highly desirable. Type 2 diabetic patients are at high risk for a Continue reading >>

Cycloset (bromocriptine Mesylate Tablets): Side Effects, Interactions, Warning, Dosage & Uses

Cycloset (bromocriptine Mesylate Tablets): Side Effects, Interactions, Warning, Dosage & Uses

( bromocriptine mesylate) Tablets, for oral use CYCLOSET Tablets contain micronized bromocriptine mesylate, a dopamine receptor agonist . Bromocriptine mesylate is chemically designated [Ergotaman-3,6,18-trione, 2-bromo-12-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-, monomethanesulfonate (salt), (5)-]. CYCLOSET is a single enantiomer with absolute configuration 5R, 8R, 2R, 5S, 11S, 12S. The structural formula of bromocriptine is shown below: Bromocriptine mesylate in CYCLOSET is a white or slightly colored micronized crystalline powder with a molecular formula of C32H40BrN5O5.CH4SO3 and a molecular weight of 750.72. CYCLOSET tablets contain bromocriptine mesylate USP in an amount equivalent to 0.8 mg. of bromocriptine. Each tablet contains the following inactive ingredients: lactose, corn starch, magnesium stearate, colloidal silicon dioxide, and citric acid. What are the possible side effects of Cycloset (Cycloset)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using this medicine and call your doctor at once if you have a serious side effect such as: chest pain, pain when you breathe, fast heart rate, rapid breathing, feeling short of breath (especially when lying down); back pain, swelling in your ankles or feet, urinating less than usual or not at all; confusion, hallucinations, feeling like you might... CYCLOSET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . CYCLOSET should not be used to treat type 1 diabetes or diabetic ketoacidosis . Limited efficacy data in combination with thiazolidinediones. Efficacy has not been confirmed in combination with insulin . The recommended do Continue reading >>

Dopamine Agonist: Cycloset (bromocriptine)

Dopamine Agonist: Cycloset (bromocriptine)

Dopamine Agonist: Cycloset (Bromocriptine) Bromocriptine is a dopamine D2 receptor agonist approved by the U.S. FDA in 2009 for treatment of type 2 diabetes patients under the trade name Cycloset. Cycloset is a quick-release formulation of bromocriptine. Unlike other medications for type 2 diabetes, Cycloset increases dopamine receptor activity in the morning, which lowers blood sugarwithout increasing insulin [1] . Bromocriptine has been in use for decades for treatment of pituitary tumors , Parkinsons disease (PD), hyperprolactinaemia , and neuroleptic malignant syndrome . The idea of using bromocriptine for the treatment of type-2 diabetes came while studying the metabolism of migrating birds ; that they develop seasonal insulin resistance and dopamine plays a role in it. Researchers found that Bromocriptine improves glycemic control lowering HbA1c levels by ~0.5%. Although the exact way bromocriptine works is still unclear, some possible mechanisms by which bromocriptine reduces glucose levels include suppression of endogenous glucose production and/or increased splanchnic glucose uptake after glucose ingestion. The most common adverse side effects associated with bromocriptine are nausea, fatigue, dizziness, vomiting and headache. The drug is also known to be associated with nasal stuffiness, nausea, headache, constrictive pericarditis,neuroleptic malignant syndrome and hypotension. The incidence of hypoglycemia was 6.9% among type 2 diabetes patients treated with bromocriptine compared to 5.3% of type 2 diabetes patients receiving placebo. Because it has a modest glucose lowering effect and frequent abdominal side effects, it is seldomly prescribed in patients with type 2 diabetes. Bromocriptine should not be used by type 1 diabetes patients. For more information Continue reading >>

Dopamine-2 Agonists (bromocriptine, Cycloset)

Dopamine-2 Agonists (bromocriptine, Cycloset)

Bromocriptine helps people with type 2 diabetes by suppressing the liver from putting sugar into the bloodstream in a process called gluconeogenesis. Currently, Bromocriptine, marketed as Cycloset is the only FDA approved dopamine-2 agonist for treatment of type 2 diabetes though it is used to treat many other conditions. Gluconeogenesis is what happens each morning before we awake to get the body some energy in order to get up and get going. Our body uses non-carbohydrate sources like amino acids in our liver and turns those into glucose. This works well in non-diabetic bodies but when it happens to people with diabetes who already have extra sugar in their bloodstream, the result is high blood sugar. So bromocriptine helps to combat this effect. An article published in the American Diabetes Association’s journal Diabetes Care states that in patients with poorly controlled diabetes treated with bromocriptine in addition to diet, metformin, sulfonylureas, or thiazolidinediones produces a slight lowering of A1c levels by 0.5% to 0.7%. In addition, bromocriptine also lowers fasting and after meal plasma free fatty acid and triglyceride levels. There was a one year prospective study which showed bromocriptine also lowered cardiovascular events (e.g. heart attacks). The image below from the Indian Journal of Endocrinology and Metabolism shows how bromocriptine (Cycloset) works: The National Health Institute (NIH) states that if you take bromocriptine (Cycloset) once a day and miss your dose, then take your next dose the next morning and be sure to never double dose to make up for a missed one. It comes as a tablet to take by mouth usually once a day with food and within 2 hours of waking. Take around the same time each day. Cautions and Side Effects of Bromocriptine (Cycl Continue reading >>

Cycloset (bromocriptine Mesylate) Is A Once-daily Prescription Pill Used With Diet And Exercise To Lower Blood Sugar Levels In Adults With Type 2 Diabetes.

Cycloset (bromocriptine Mesylate) Is A Once-daily Prescription Pill Used With Diet And Exercise To Lower Blood Sugar Levels In Adults With Type 2 Diabetes.

Are allergic to bromocriptine or any of the other ingredients in CYCLOSET Have fainting (syncopal) migraine headaches or take medicines for migraines called ergots. Ask your health care provider or pharmacist for a list of these medicines, if you are not sure whether you take any. Before taking CYCLOSET, tell your health care provider about all medical conditions, including if you: Have type 1 diabetes mellitus or diabetic ketoacidosis Have or have had low blood pressure (hypotension) Have or have had a mental health condition, especially a psychotic disorder Are pregnant or plan to become pregnant. It is not known if CYCLOSET will harm your unborn baby. Talk with your health care provider if you are pregnant or plan to become pregnant. Tell your health care provider about all medicines you take (prescription, non-prescription, vitamins and supplements), especially those for: Mental health conditions, especially anti-psychotic medicines CYCLOSET may cause serious side effects, including: Low blood pressure, fainting, or severe dizziness after you stand up from a sitting or lying position The most common side effects of CYCLOSET include: Fatigue (somnolence) if you have somnolence, do not drive or use other heavy equipment until the somnolence is better Low blood sugar (hypoglycemia), especially when used with another type of diabetes medicine known as a sulfonylurea Tell your health care provider if you have any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please click here for full Prescribing Information, including Patient Information. Continue reading >>

Bromocriptine In Type 2 Diabetes Mellitus

Bromocriptine In Type 2 Diabetes Mellitus

Bromocriptine in type 2 diabetes mellitus Department of Endocrinology, M. S. Ramaiah Hospital, Bangalore, India 1Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, Haryana, India Corresponding Author: Dr. Shivaprasad C., Department of Endocrinology, M. S. Ramaiah Hospital, Bangalore, India. E-mail: [email protected] Author information Copyright and License information Copyright Indian Journal of Endocrinology and Metabolism This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article has been cited by other articles in PMC. Bromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an abnormally elevated hypothalamic drive for increased plasma glucose, free fatty acids, and triglycerides in insulin-resistant patients. Randomized controlled trials have shown that bromocriptine-QR lowers glycated hemoglobin by 0.4 0.8% either as monotherapy or in combination with other anti-diabetes medications. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson's disease, and apart from nausea, the drug is well-tolerated. The novel mechanism of action, good side effect profile, and its effects to reduce cardiovascular event rates make it an attractive option for the treatment of type 2 diabetes. Keywords: Bromocriptine, circadian rhythm, diabetes, insulin resistance, quick release formulation Type 2 diabetes mellitus (T2DM) is a chro Continue reading >>

Bromocriptine: A Sympatholytic, D2-dopamine Agonist For The Treatment Of Type 2 Diabetes

Bromocriptine: A Sympatholytic, D2-dopamine Agonist For The Treatment Of Type 2 Diabetes

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes Diabetes Division, University of Texas Health Science Center, San Antonio, Texas Corresponding author: Ralph A. DeFronzo, [email protected] . Author information Copyright and License information Disclaimer Copyright 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See for details. This article has been corrected. See Diabetes Care. 2011 June; 34(6): 1442 . This article has been cited by other articles in PMC. Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h of awakening is believed to augment low hypothalamic dopamine levels and inhibit excessive sympathetic tone within the central nervous system (CNS), resulting in a reduction in postmeal plasma glucose levels due to enhanced suppression of hepatic glucose production. Bromocriptine has not been shown to augment insulin secretion or enhance insulin sensitivity in peripheral tissues (muscle). Addition of bromocriptine to poorly controlled type 2 diabetic patients treated with diet alone, metformin, sulfonylureas, or thiazolidinediones produces a 0.50.7 decrement in HbA1c. Bromocriptine also reduces fasting and postmeal plasma free fatty acid (FFA) and triglyceride levels. In a 52 double-blind, placebo-controlled study in type 2 diabetic patients, bromocriptine reduced the composite cardiovascular end point by 40%. The mechanism of the drugs beneficial effect on cardiovascular disease remains to be determined. Type 2 diabetes is a chronic metabolic disorde Continue reading >>

Novel Diabetes Drug Cycloset Approved

Novel Diabetes Drug Cycloset Approved

Last week, the U.S. Food and Drug Administration (FDA) approved a new drug for treating Type 2 diabetes. Called Cycloset, the drug is actually a new version of the older drug bromocriptine, which has been used at higher doses to treat people with Parkinson disease. The new drug, which is to be taken once a day, within two hours of waking up, with food, has been shown to lower HbA1c levels (a measure of average blood glucose) in people with Type 2 diabetes more than a placebo . In a year-long study of over 3,000 adults, 39% of people taking Cycloset reached the studys HbA1c goal, compared to 11% of people who took the placebo. According to Cyclosets press materials, studies have also shown that one daily dose of the drug helps lower postmeal rises in peoples blood glucose levels all day. According to animal studies, Cycloset works by boosting the activity of a chemical called dopamine in the brain. This, in turn, resets the bodys biological clock to help control its metabolism. Studies of the biological clocks of migrating birds and hibernating animals, which become more insulin resistant during certain times of the year, helped inspire this drugs development. People taking Cycloset in the 3,000-person study were also less likely to have a heart attack or stroke or to die of heart disease while taking the drug. Earlier this year, the FDA tightened heart-safety standards for new diabetes drugs (check out the Diabetes Flashpoints feature FDA: Stifler or Savior? for more details about this decision). When this drug will reach the market is unclear, since its manufacturer, VeroScience, Inc., is a small company. An interesting article about this drugs 20-plus year journey from laboratory to market appeared last week in The Boston Globe. Disclaimer of Medical Advice: You unde Continue reading >>

Under The Radar: Bromocriptine Or Cycloset Works In Brain To Regulate Insulin - Pills - Diabetes | Healthcentral

Under The Radar: Bromocriptine Or Cycloset Works In Brain To Regulate Insulin - Pills - Diabetes | Healthcentral

T heres a new drug for type 2 diabetes, just approved by the FDA. Actually, its an old drug, that has been approved for many years for other medical conditions, and which just got approval for treating diabetes. I sort of stumbled across the news of its approval after a colleague sent out an e-mail (which indicated that he too was unaware of it until recently). With all the hullabaloo about several recent FDA reviews of diabetes drugs seeking approval for marketing in the United States, it was truly a surprise to me to find one that snuck through under the radar, without a huge sales push from the manufacturer nor attention from the media. Heck, even the companys website doesnt have a press release that the drug has been approved So, what gives? Turns out that a drug thats been on the market for many years, bromocriptine (brand name Cycloset), just got FDA approval for treating blood glucose in type 2 diabetes. Theres a discussion about the approval on the Internet at BioWorld that spells out why theres no publicity: the maker, VeroScience LLC and its marketing partner, S2 Therapeutics, are now looking for a major pharmaceutical company to partner with in the manufacturing and marketing of Cycloset. (S2 Therapeutics is so small that I cant even find a website for them!) So two small companies did the diabetes studies on a medication thats already approved for other indications, and now can sell it if they can find factories of sufficient size to manufacture enough product, and can partner with someone with the media muscle to pitch their product in a crowded marketplace. The approved labeling information for Cycloset is at the FDA website . Cycloset is approved as a once-daily product, to be administered in the morning to be taken within two hours after waking in the m Continue reading >>

Cycloset (bromocriptine) Uses, Dosage, Side Effects - Drugs.com

Cycloset (bromocriptine) Uses, Dosage, Side Effects - Drugs.com

This medication guide provides information about the Cycloset brand of bromocriptine. Parlodel is another brand of bromocriptine used to treat parkinson disease that is not covered in this medication guide. Cycloset is a quick release formulation of micronized bromocriptine mesylate and is used together with diet and exercise to treat type 2 diabetes mellitus . Cycloset is not for treating type 1 diabetes. Love Your Dad? Here's 10 Heart-Healthy Gifts For Father's Day You should not use Cycloset if you are breast-feeding, if you have migraine headaches that cause you to faint, or if you are in a state of diabetic ketoacidosis (Call your doctor for treatment with insulin). You should not breast-feed a baby while taking Cycloset. Tell your doctor right away if you become pregnant while taking this medicine. You should not use Cycloset if you are allergic to bromocriptine or to an ergot medicine (Ergomar, Cafergot, Migergot, D.H.E. 45, Migranal, Methergine). You should not use Cycloset if: you have migraine headaches that cause you to faint; or you are in a state of diabetic ketoacidosis (Call your doctor for treatment with insulin). Cycloset may contain lactose. Before taking this medicine, tell your doctor if you have a hereditary form of galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption. To make sure you can safely take this medicine, tell your doctor if you have any of these other conditions: high or low blood pressure, heart disease, or a history of heart attack; a stomach ulcer or history of stomach or intestinal bleeding; or a history of mental illness or psychosis. FDA pregnancy category B. Cycloset is not expected to harm an unborn baby. However, a pituitary tumor in the mother can expand during pregnancy. High blood pressure can Continue reading >>

Old Drug, New Trick Cycloset

Old Drug, New Trick Cycloset

FDA Approves A New First In Class Diabetes Drug Cycloset People with Type 2 diabetes may soon get a very different treatment approach University of Florida: College of Pharmacy Bromocriptine has historically been used for Parkinsons, but this old drug has a new trick. Marketed under the name Cyclosert, it was approved by the FDA for treating Type 2 diabetes on May 6th, 2009. It is a once daily quick release low dose form of bromocriptine, acts on the central nervous system to improve glucose tolerance and insulin resistance centrally. This is accomplished through resetting the neuroendocrine rhythms, which have been shown to be associated changes in metabolism leading to obesity and insulin resistance. These metabolic changes likely occur in the suprachiasmatic nuclei located in the hypothalamus, and are regulated by dopamine and serotonin. The agonist activity at dopamine receptors of bromocriptine act on the suprachiasmatic nuclei and inhibits the serotonin effects to reset the neuronal activities, and resulting in improved glucose tolerance and insulin resistance. Bromocriptine also reduces catecholamine levels by decreasing sympathetic tone, resulting in decreased lipolysis and free fatty acids. There is also an increase in protein synthesis and breakdown into amino acids, coupled with reduced breakdown of amino acids leaving them for the increased protein synthesis. This causes an increase in energy usage resulting in loss of body fat. Paraventricular hypothalamic reduction also results in deceased glucose production from the liver. In short, Cyclosert once daily every morning can regulate metabolism improving glucose tolerance and insulin resistance, as well as reducing body fat through a decrease in sympathetic tone and increased energy usage. It will be interes Continue reading >>

More in diabetes